Plant Name: Hydrodictyon reticulatum
Taxonomic Information:
Plant ID: NPO17557
Plant Latin Name: Hydrodictyon reticulatum
Taxonomy Genus: Hydrodictyon
Taxonomy Family: Hydrodictyaceae
Plant External Links:
NCBI TaxonomyDB:
3107
Plant-of-the-World-Online:
n.a.
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| HRH3; HRH4; HRH2; HRH1; | |
| NPSR1; TSHR; | |
| BLM; GLA; | |
| GABRR2; | |
| KDM4E; | |
| NFKB1; | |
| LMNA; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | GLA | Alpha-galactosidase A | P06280 | CHEMBL2524 |
| GABA-A receptor | GABRR2 | GABA receptor rho-2 subunit | P28476 | CHEMBL2375 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Small molecule receptor (family A GPCR) | HRH3 | Histamine H3 receptor | Q9Y5N1 | CHEMBL264 |
| Small molecule receptor (family A GPCR) | HRH4 | Histamine H4 receptor | Q9H3N8 | CHEMBL3759 |
| Small molecule receptor (family A GPCR) | HRH2 | Histamine H2 receptor | P25021 | CHEMBL1941 |
| Small molecule receptor (family A GPCR) | HRH1 | Histamine H1 receptor | P35367 | CHEMBL231 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0060089; molecular transducer activity | GO:0004969; histamine receptor activity | 2.587E-12 | 5.634E-08 | HRH1, HRH2, HRH3, HRH4 |
| BP | GO:0065007; biological regulation | GO:0045761; regulation of adenylate cyclase activity | 4.224E-06 | 1.840E-02 | HRH3, HRH4, TSHR |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 7.305E-06 | 2.434E-02 | CYP2C19, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0007186; G-protein coupled receptor signaling pathway | 1.332E-05 | 2.637E-02 | GABRR2, HRH1, HRH2, HRH3, HRH4, NPSR1, TSHR |
| BP | GO:0008152; metabolic process | GO:0032769; negative regulation of monooxygenase activity | 2.673E-05 | 4.158E-02 | GLA, NFKB1 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 3.206E-05 | 4.654E-02 | CYP2C19, CYP3A4 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 1.830E-08 | 1.537E-06 | GABRR2, HRH1, HRH3, HRH2, HRH4, TSHR |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 1.828E-04 | 7.676E-03 | CYP3A4, CYP2C19 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 1.039E-03 | 2.910E-02 | CYP3A4, CYP2C19 |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 1.464E-03 | 3.073E-02 | CYP3A4, CYP2C19 |
| 09140 Cellular Processes | 09143 Cell growth and death | hsa04210 | Apoptosis | 4.190E-03 | 7.039E-02 | LMNA, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04020 | Calcium signaling pathway | 6.827E-03 | 9.558E-02 | HRH1, HRH2 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 8.286E-03 | 9.943E-02 | NFKB1, TSHR |
| 09100 Metabolism | 09107 Glycan biosynthesis and metabolism | hsa00603 | Glycosphingolipid biosynthesis - globo series | 9.759E-03 | 1.025E-01 | GLA |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 4.658E-02 | 1.038E-01 | NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05220 | Chronic myeloid leukemia | 4.992E-02 | 1.038E-01 | NFKB1 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | HRH3; |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | HRH3; |
| G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | HRH3; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | HRH4; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | HRH3; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | HRH4; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cough | R05 | HRH1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | HRH3; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Allergic skin disorders | L00-L99 | HRH1; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | HRH1; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | HRH3; |
| C00-D49: Neoplasms | Allergic conjunctivitis | C91.0, H10, H10.45, T78.4 | HRH1; |
| NA: NA | Allergic disorders | NA | HRH1; |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | HRH1; HRH3; HRH4; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Musculoskeletal pain | R52, G89 | HRH3; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | HRH1; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Anesthesia | R20.0 | HRH1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | HRH3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; HRH1; HRH3; |
| NA: NA | Morning sickness | NA | HRH1; |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | HRH1; |
| NA: NA | Vomiting | NA | HRH1; |
| H60-H95: Diseases of the ear and mastoid process | Vertigo meniere's disease | H81, H81.0, R42 | HRH1; |
| NA: NA | Vertigo's disease | NA | HRH1; |
| C00-D49: Neoplasms | Cancer | C00-C96 | NFKB1; HRH1; |
| NA: NA | Common cold | NA | HRH1; |
| J00-J99: Diseases of the respiratory system | Seasonal and perennial allergic rhinitis and vasomotor rhinitis | J30 | HRH1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | HRH3; |
| NA: NA | Vasomotor rhinitis | NA | HRH1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sleep disorders | F51, G47 | HRH1; HRH3; |
| NA: NA | Meniere's disease | NA | HRH1; |
| NA: NA | Perennial and seasonal allergic rhinitis | NA | HRH1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; |
| NA: NA | Urticaria | NA | HRH1; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Nausea | R11 | HRH1; |
| G00-G99: Diseases of the nervous system G00-G99 | Narcolepsy | G47.4 | HRH3; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | HRH1; |
| NA: NA | Coughs | NA | HRH1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | HRH1; |
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | HRH1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | HRH1; HRH3; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obese insulin-resistant disorders | E11 | HRH3; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | HRH1; HRH4; |
| NA: NA | Itching | NA | HRH1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | HRH3; |
| NA: NA | Respiratory allergies | NA | HRH1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Excessive daytime sleepiness | F51.1, G47.1 | HRH3; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | HRH3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | HRH3; |
| H00-H59: Diseases of the eye and adnexa | Ocular allergy | H00-H59 | HRH1; |
| J00-J99: Diseases of the respiratory system | Hay fever | J30 | HRH1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | HRH3; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | HRH1; HRH3; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Dry cough | R05 | HRH1; |
| J00-J99: Diseases of the respiratory system | Nasal congestion | J34.89 | HRH1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | HRH1; |
| NA: NA | Hypersensitivity reactions | NA | HRH1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Eating disorder | E66, F50, I10-I16, I50 | HRH3; |
>> Profiles of ingredients and activity landscape
>> Targets derived from weak experimental activities
